List of FDA Orphan Drugs
GARD has information from the Food and Drug Administration (FDA) on treatments approved for rare diseases, known as orphan products/drugs. The Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare diseases. The FDA Office of Orphan Products Development determines if a drug qualifies as an orphan product. The following information comes from the FDA database of orphan drug designations and approvals. You can output the data into an Excel spreadsheet from the FDA website. More information on orphan drug development is available from Global Genes and Orphanet.
S
- Scurvy
- Severe combined immunodeficiency
- Sezary syndrome
- Short bowel syndrome
- Sickle cell anemia
- Sjogren syndrome
- Small cell lung cancer
- Soft tissue sarcoma
- Soft tissue sarcoma childhood
- Spinal muscular atrophy
- Spinal muscular atrophy 1
- Spinal muscular atrophy type 2
- Spinal muscular atrophy type 3
- Spinal muscular atrophy type 4
- Squamous cell carcinoma
- Squamous cell carcinoma of the head and neck
- Status epilepticus
- Stomach cancer
- Stomach cancer, childhood
- Subependymal giant cell astrocytoma
- Superficial spreading melanoma
- Systemic mastocytosis
No hay comentarios:
Publicar un comentario